Seeking Alpha

GNVC
GenVec, Inc.

5/26/2012, 6:05 PM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
GNVC Market Currents more »
  • March 30, 2010 GenVec (GNVC) tumbles 71.9% after it discontinues a trial for its lead gene therapy drug for pancreatic cancer. Interim results showed it was unlikely to become effective.
GNVC Cramer more »
Currently, there are no Cramer articles on GNVC.
GNVC Instablog posts more »
Write a post on GNVC
GNVC StockTalks
GNVC vs. ETF Alternatives
Company Description

GenVec, Inc. (GenVec, we, our, or the Company) is a clinical stage biopharmaceutical company developing novel, gene-based therapeutic drugs and vaccines. Our lead therapeutic product candidate, TNFeradeTM biologic (TNFerade), is being developed for use in the treatment of cancer. TNFerade is... More

Sector: Healthcare
Industry: Biotechnology
Country: United States